RESEARCH CORPORATION 
405 LEXINGTON AVENUE, NEW YORK, NEW YORK 10017 
JAMES STACY COLES 
PRESIDENT 
November 30, 1976 
Donald S. Frederickson, M.D. 
Director 
Public Health Service 
National Institutes of Health 
Bethesda, Maryland 20014 
Dear Dr. Frederickson: 
This is in response to your letter of November 17, 1976, 
inquiring about Research Corporation's role in the sup- 
port or conduct of recombinant desoxyribonucleic acid (DNA ) 
research, and the potential application of NIH guidelines 
to our research activities in this area. 
In response. Research Corporation does not conduct any 
research itself. Rather, it supports research on college 
and university campuses through a program of grants made 
in response to proposals for specific research projects. 
Thus, we are conducting no research in this area. 
With reference to support of research in this area, we are 
at present supporting no such projects. 
I note from the summary minutes of the November 4, 1976 meet- 
ing of the Interagency Committee on Recombinant DNA Research 
that one of the topics covered during your review of the 
NIH guidelines was "the question of patenting certain inven- 
tions resulting from recombinant DNA research." Recently, at 
the explicit request of the Chief of the Patents Branch of 
the Office of the Secretary of the Department of Health, Edu- 
cation and Welfare, we have undertaken to patent an invention 
from the University of Alabama in Birmingham, involving a 
[ 202 ] 
A FOUNDATION FOR THE ADVANCEMENT OF SCIENCE 
